Physician profile
Robert P Fein
NPI 1801887286
$4,522.30
in general payments reported to CMS, 2019-2025
57 companies · $898 in 2025
The $898 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $462 · 2021: $26.27 · 2022: $502 · 2023: $1,019 · 2024: $1,138 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,953 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.82 |
| Education | $102.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $612.80 | 2020-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $265.62 | 2019-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $244.13 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $197.51 | 2019-2025 | |
| Amgen INC. | $177.14 | 2019-2023 | Lumakras |
| Pfizer INC. | $146.90 | 2019-2025 | |
| Blueprint Medicines Corporation | $138.11 | 2023-2024 | Ayvakit |
| Karyopharm Therapeutics INC. | $137.44 | 2020-2023 | Xpovio |
| Exelixis INC. | $128.47 | 2022 | |
| Epizyme, INC. | $125.00 | 2022 | |
| Astellas Pharma US INC | $122.76 | 2023-2025 | Padcev, Xospata |
| Incyte Corporation | $118.81 | 2019-2025 | Jakafi |
| Genentech USA, INC. | $112.02 | 2019-2025 | Phesgo, Polivy, Itovebi |
| Merck Sharp & Dohme LLC | $111.32 | 2019-2024 | Keytruda, Lynparza, Lenvima |
| Pharmacosmos Therapeutics INC. | $104.83 | 2023-2025 | Monoferric, Cosela |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $104.58 | 2020-2025 | Onivyde, Somatuline Depot |
| Regeneron Healthcare Solutions, INC. | $103.87 | 2024-2025 | Libtayo |
| Mirati Therapeutics, INC. | $94.19 | 2023-2024 | Krazati |
| Janssen Biotech, INC. | $87.93 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Glaxosmithkline, LLC. | $84.88 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Novartis Pharmaceuticals Corporation | $84.54 | 2019-2025 | |
| Abbvie INC. | $75.78 | 2019-2025 | |
| Celgene Corporation | $67.86 | 2023-2025 | Reblozyl |
| Gilead Sciences, INC. | $67.16 | 2021-2025 | Trodelvy |
| Janssen Scientific Affairs, LLC | $58.67 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $52.10 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.48 | 2024-2025 | |
| Eisai INC. | $49.86 | 2019-2025 | |
| Stemline Therapeutics INC. | $44.82 | 2024 | Orserdu |
| Caris Mpi, INC. | $44.79 | 2025 | Mi Cancer Seek |
| Genzyme Corporation | $43.50 | 2023-2025 | |
| Adc Therapeutics America, INC. | $42.38 | 2023 | |
| Deciphera Pharmaceuticals INC. | $38.83 | 2025 | Qinlock, Romvimza, Tgct |
| Apellis Pharmaceuticals, INC. | $37.74 | 2024 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $36.40 | 2019 | |
| Alexion Pharmaceuticals, INC. | $36.40 | 2023 | Ultomiris |
| Puma Biotechnology, INC. | $36.40 | 2024-2025 | |
| Beigene USA, INC. | $32.78 | 2024 | Brukinsa |
| Octapharma USA, INC. | $32.33 | 2024 | Panzyga |
| Novocure INC. | $29.34 | 2025 | Optune Lua (Novottf-200t) |
| Seagen INC. | $29.04 | 2019 | |
| Lilly USA, LLC | $28.50 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Beone Medicines USA, INC. | $27.83 | 2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $26.85 | 2024 | Clonoseq |
| Myriad Genetic Laboratories, INC. | $25.10 | 2025 | Myrisk |
| Taiho Oncology, INC. | $23.38 | 2025 | |
| Array Biopharma INC | $21.80 | 2024 | Mektovi, Tukysa, Braftovi |
| Genmab U.S., INC. | $20.49 | 2025 | Epkinly |
| Emmaus Medical, INC. | $20.36 | 2023 | Endari |
| Sumitomo Pharma America, INC. | $18.95 | 2025 | Orgovyx |
| Jazz Pharmaceuticals INC. | $18.39 | 2025 | |
| Dendreon Pharmaceuticals LLC | $17.92 | 2024 | Provenge |
| Agios Pharmaceuticals, INC. | $17.25 | 2023 | Pyrukynd |
| Sobi, INC | $16.77 | 2024 | |
| Amneal Pharmaceuticals LLC | $15.34 | 2025 | Alymsys |
| Alnylam Pharmaceuticals INC. | $13.86 | 2024 | Givlaari |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.